Anixa BiosciencesANIX -2.66%27 Days Payable is 0.00 as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review. Among 707 Biotechnology companies, Anixa Biosciences ranks worse than 141442.57% on this metric.
The historical rank and industry rank for Anixa Biosciences's Days Payable or its related term are showing as below:
During the past 13 years, Anixa Biosciences's highest Days Payable was 1482.60. The lowest was 174.44. And the median was 584.01.
ANIX's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 113.76 * Ranked among companies with meaningful Days Payable only.
Anixa Biosciences's Days Payable
stayed the same
from Apr. 2025 (0.00) to Apr. 2026 (0.00).
stayed the same
Anixa Biosciences Days Payable Related Terms
Anixa Biosciences Days Payable Historical Data
* Premium members only.
The historical data trend for Anixa Biosciences's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Anixa Biosciences's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anixa Biosciences Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Days Payable distribution charts can be found below:
* The bar in red indicates where Anixa Biosciences's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Anixa Biosciences's Days Payable for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Anixa Biosciences (ANIX) has a Days Payable of 0.00 as of Apr. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Anixa Biosciences and its competitors. Over the past decade, Anixa Biosciences' Days Payable has ranged from 174.44 to 1,482.60. According to the industry distribution chart, Anixa Biosciences ranks #999999 out of 707 companies in the Biotechnology industry.
Is Anixa Biosciences' Days Payable too high?
Anixa Biosciences' current Days Payable is 0.00. Over the past 10 years, this metric has ranged from a low of 174.44 to a high of 1,482.60. Based on the distribution chart, Anixa Biosciences ranks #999999 out of 707 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Days Payable compare to PYPD and LONA?
According to the Biotechnology industry distribution chart, Anixa Biosciences ranks #999999 out of 707 companies for Days Payable. This places Anixa Biosciences in the lower half of its industry. The industry median Days Payable is 113.76. Historically, Anixa Biosciences' own Days Payable has ranged from 174.44 to 1,482.60 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 113.76, based on 707 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Anixa Biosciences and its competitors. For the Biotechnology industry, the median Days Payable is 113.76 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anixa Biosciences's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Days Payable of 0.00. The current Days Payable is 0.00. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Days Payable is 0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score
Get the complete analysis for ANIX
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ANIX has been successfully added to your 
